Biogen completes acquisition of RayThera
BIIB•Lead program status
RayThera’s lead program entered Phase 1 development in July 2026.
Biogen completes RayThera acquisition
Biogen completed its acquisition of privately held RayThera, adding small-molecule immunology programs to its pipeline.
The deal expands Biogen’s immunology portfolio with multiple assets targeting immune-mediated conditions across several indications.
Related News
Perpetua Resources reports high-grade gold and antimony discoveries at Stibnite project in Idaho
PPTA•
Beeline Holdings issues $350,000 9% promissory note to WVP Emerging Manager Onshore Fund for $300,000
BLNE•
